schizophrenia, Bristol-Myers Squibb
Valued at a market cap of $113.1 billion, Bristol-Myers Squibb Company (BMY) is a leading global biopharmaceutical company ...
Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...
Bristol Myers Squibb (BMY) has been one of the most searched ... Over the past month, shares of this biopharmaceutical company have returned -0.9%, compared to the Zacks S&P 500 composite's ...
Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat ...
Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.74 which represents a slight increase of $0.38 or 0.69% from the prior close of $55.36. The stock opened at $55.5 and ...
Wedmont Private Capital grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 29.5% during the 4th ...
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...
View Bristol-Myers Squibb Company (BMY) current and estimated P/E ratio data provided by Seeking Alpha.
Bristol Myers Squibb announced that it has been named in the prestigious Dow Jones Sustainability Index (DJSI) for the second ...
Arsenal Biosciences, Inc., a clinical-stage programmable cell therapy company, announced Monday that drug maker Bristol-Myers Squibb ...